Drug

Dacarbazine

In clinical development

Emerging researchLate-stage developmentSteady momentum

Also known as 4-(dimethyltriazeno)imidazole-5-carboxamide, 5-(dimethyltriazeno)imidazole-4-carboxamide, DIC, DTIC+10 more

4-(dimethyltriazeno)imidazole-5-carboxamide, 5-(dimethyltriazeno)imidazole-4-carboxamide, DIC, DTIC, Dimethyl-triazeno-imidazole carboxamide, ICDMT, Imidazole carboxamide, Dacarbazin, Dacarbazina, 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide, 4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide, 5-(3,3-dimethyltriazeno)imidazole-4-carboxamide, Dacarbazinum.

RxNorm3098 ChEMBLCHEMBL476 ATCL01AX04UNII7GR28W0FJI

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q1 2032 · ClinicalTrials.gov

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Clinical trial2026-07-09Results expected Q2 2031 · ClinicalTrials.gov

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Clinical trial2026-07-08Results expected Q3 2030 · ClinicalTrials.gov

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Clinical trial2026-06-17Results expected Q1 2027 · ClinicalTrials.gov

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Clinical trial2026-06-10Results expected Q1 2028 · ClinicalTrials.gov

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Clinical trial2026-06-02Completed · ClinicalTrials.gov

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

Clinical trial2026-05-22Results posted · ClinicalTrials.gov

Estimating the global burden of Epstein-Barr virus-related cancers.

Research2021-10-27Journal of cancer research and clinical oncology

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

Research2021-09-01The New England journal of medicine

Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma.

Research2020-09-30Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nivolumab in previously untreated melanoma without BRAF mutation.

Research2014-11-16The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dacarbazine

Aliases & brands

4-(dimethyltriazeno)imidazole-5-carboxamide5-(dimethyltriazeno)imidazole-4-carboxamideDICDTICDimethyl-triazeno-imidazole carboxamideICDMTImidazole carboxamideDacarbazinDacarbazina4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide4-(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide5-(3,3-dimethyltriazeno)imidazole-4-carboxamideDacarbazinum

RxNorm CUI

3098

ChEMBL ID

CHEMBL476

ATC codes

L01AX04

UNII

7GR28W0FJI

Clinical trials

155 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

155

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 155

Phase 18Phase 1 / 212Phase 276Phase 2 / 33Phase 350Phase 41Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine in Indian Patients With Untreated Stage 3/4 Classical Hodgkin Lymphoma

RecruitingPH IVTakedan=1242028

A Phase II/III Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET/CT Assessment

RecruitingPH II/IIIChildren's Cancer Group, Chinan=962039

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

RecruitingPH IIIGustave Roussy, Cancer Campus, Grand Parisn=8002032

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

RecruitingPH IIIKey trialUniversity College, Londonn=1,0422032

RecruitingPH IIIImmatics US, Inc.n=3602031

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

CompletedN/AMemorial Sloan Kettering Cancer Centern=1182026

Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)

CompletedPH IIStanford Universityn=172026

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

CompletedPH IIIKey trialTakedan=1,3342026

A Phase 2, Single Arm Study on Dacarbazine (DTIC) Followed by Immunotherapy Re-challenge in Unresectable or Metastatic Melanoma With Primary Resistance to PD-1/PD-L1 or PD-1 + CTLA-4 Blockade

CompletedPH IIUniversity of Erlangen-Nürnberg Medical Schooln=382026

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors

CompletedPH IAstraZenecan=1402025

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

CompletedPH IIImmunocore Ltdn=3782025

Research activity

6 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20082022

Most influential

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

The New England journal of medicine · 2011 · 5,684 cites

Nivolumab in previously untreated melanoma without BRAF mutation.

The New England journal of medicine · 2015 · 4,269 cites

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

The New England journal of medicine · 2021 · 685 cites

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008 · 182 cites

Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · 174 cites

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Melanoma4

Related drugs

6 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Bleomycin

Studied across 9 of the same disease areas as Dacarbazine in the shared literature.

9 shared diseases1 shared paper

Doxorubicin

Studied across 9 of the same disease areas as Dacarbazine in the shared literature.

9 shared diseases1 shared paper

Vinblastine

Studied across 9 of the same disease areas as Dacarbazine in the shared literature.

9 shared diseases1 shared paper

Pembrolizumab

Studied across 6 of the same disease areas as Dacarbazine in the shared literature.

6 shared diseases1 shared paper

Tebentafusp

Studied across 4 of the same disease areas as Dacarbazine in the shared literature.

4 shared diseases1 shared paper

Vemurafenib

Studied across 2 of the same disease areas as Dacarbazine in the shared literature.

2 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials